Contribution of the laboratory in case of resistance to acyclovir of herpes simplex and varicella zoster virus;Apport du laboratoire en cas de résistance à l'aciclovir des virus herpes simplex et varicelle zona

Annales de Biologie Clinique

Volumn 61, Issue 1, 2003, Pages 33-40

  Morfin, F ^a   Frobert, E ^a   Thouvenot, D ^a  

^a HOSPICES CIVILS DE LYON   (France)

Author keywords

Antiviral assays; Herpes simplex virus; Mutations; Resistance; Varicella zoster virus

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT;

ANTIBIOTIC RESISTANCE; CHICKENPOX; DRUG EFFECT; GENETICS; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HERPES ZOSTER; HUMAN; MUTATION; PHENOTYPE; REVIEW; VARICELLA ZOSTER VIRUS;

ACYCLOVIR; ANTIVIRAL AGENTS; CHICKENPOX; DRUG RESISTANCE, VIRAL; HERPES SIMPLEX; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HUMANS; MUTATION; PHENOTYPE; SIMPLEXVIRUS;

HUMAN HERPESVIRUS 3; SIMPLEXVIRUS;

EID: 0037274305     PISSN: 00033898     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Perry CM, Faulds D. Valacyclovir: a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Drugs 1996; 52: 754-72.
2. Field AK, Biron KK. The end of innocence revisited: resistance of Herpesviruses to antiviral drugs. Clin Microbiol Rev 1994; 7: 1-13.
3. Straus SE, Takiff HE, Seidlin M, et al. Suppression of frequently recurring genital herpes: a placebo-controlled double-blind trial of oral acyclovir. N Engl J Med 1984; 310: 1545-50.
4. Kost RG, Hill EL, Tigges M, Straus SE. Brief report: recurrent acyclovir-resistant genital herpes in an immunocompetent patient. N Engl J Med 1993; 329: 1777-82.
5. Mouly F, Baccard M, Scieux C, et al. Chronic recurrent acyclovir-resistant genital herpes in an immunocompetent patient. Dermatology 1995; 190: 177.
6. McLaren C, Corey L, Dekker C, Barry DW. In vitro sensitivity to acyclovir in genital herpes simplex viruses from acyclovir-treated patients. J Infect Dis 1983; 148: 868-75.
7. Chen Y, Scieux C, Garrait V, et al. Resistant herpes simplex virus type 1 infection: an emerging concern after allogeneic stem cell transplantation. Clin Infect Dis 2000; 31: 927-35.
8. Ljungman P, Ellis MN, Hackman RC, Shepp DH, Meyers JD. Acyclovir-resistant herpes simplex virus causing pneumonia after marrow transplantation. J Infect Dis 1990; 162: 244-8.
9. Youle MM, Hawkins DA, Collins P, et al. Acyclovir-resistant herpes in AIDS treated with foscarnet. Lancet 1988: 2; 341-2.
10. Morfin F, Thouvenot D, Aymard M, Souillet G. Reactivation of acyclovir-resistant thymidine kinase-deficient herpes simplex virus harbouring single base insertion within a 7 Gs homopolymer repeat of the thymidine kinase gene. J Med Virol 2000; 62: 247-50.
11. Safrin S, Crumpacker C, Chatis P, et al. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. N Engl J Med 1991; 325: 551-5.
12. Englund JA, Zimmerman ME, Swierkosz EM, Goodman JL, Scholl DR, Balfour HH Jr. Herpes simplex virus resistant to acyclovir: a study in a tertiary care center. Ann Intern Med 1990; 112: 416-22.
13. Nugier F, Colin JN, Aymard M, Langlois M. Occurrence and characterization of acyclovir-resistant herpes simplex virus isolates: report on a two-year sensitivity screening survey. J Med Virol 1992; 36: 1-12.
14. Fife KH, Crumpacker CS, Mertz GJ, Hill EL, Boone GS Recurrence and resistance patterns of herpes simplex virus following cessation of > or = 6 years of chronic suppression with acyclovir. Acyclovir Study Group. J Infect Dis 1994; 169: 1338-41.
15. Christophers J, Clayton J, Craske J, et al. Survey of resistance of herpes simplex virus to acyclovir in northwest england. Antimicrob Agents Chemother 1998; 42: 868-72.
16. Safrin S, Berger TG, Gilson I, et al. Foscarnet therapy in five patients with AIDS and acyclovir-resistant varicella-zoster virus infection. Ann Intern Med 1991; 115: 19-21.
17. Boivin G, Edelman CK, Pedneault L, Talarico CL, Biron KK, Balfour HH. Phenotypic and genotypic characterization of ACV-resistant varicella-zoster viruses isolated from persons with AIDS. J Infect Dis 1994; 170: 68-75.
18. Morfin F, Thouvenot D, De Turenne-Tessier M, Lina B, Aymard M, Ooka T. Phenotypic and genetic characterization of thymidine kinase from clinical strains of varicella-zoster virus resistant to acyclovir. Antimicrob Agents Chemother 1999; 43: 2412-6.
19. Crassard N, Souillet AL, Morfin F, Thouvenot D, Claudy A, Bertrand Y. Acyclovir-resistant varicella infection with atypical lesions in a non-HIV leukemic infant. Acta Paediat 2000; 89: 1497-9.
20. Collins P, Ellis MN. Sensitivity monitoring of clinical isolates of herpes simplex virus to acyclovir. J Med Virol 1993; Suppl. 1: 58-66.
21. Safrin S, Phan L, Elbeik T. A comparative evaluation of three methods of antiviral susceptibility testing of clinical herpes simplex virus isolates. Clin Diagn Virol 1995; 4: 81-91.
22. Langlois M, Allard JP, Nugier F, Aymard M. A rapid anal automated colorimetric assay for evaluating the sensitivity of herpes simplex strains to antiviral drugs. J Biol Stand 1986; 14: 201-11.
23. Danve C, Morfin F, Thouvenot D, Aymard M. A screening dye-uptake assay to evaluate in vitro susceptibility of herpes simplex virus to acyclovir. J Virol Meth 2002: 105: 207-17.
24. Kudo E, Shiota H, Naito T, Satake K, Itakura M. Polymorphisms of thymidine kinase gene in herpes simplex virus type 1: analysis of clinical isolates from herpetic keratitis patients and laboratory strains. J Med Virol 1998; 56: 151-8.
25. Morfin F, Souillet G, Bilger K, Ooka T, Aymard M, Thouvenot D. Genetic characterization of the thymidine kinase from acyclovir-resistant and acyclovir-susceptible herpes simplex virus type 1 isolated from bone marrow transplant recipients. J Infect Dis 2000; 182: 290-3.
26. Bestman-Smith J, Schmit I, Papadopoulou B, Boivin G. Highly reliable heterologous system for evaluating resistance of clinical herpes simplex virus isolates to nucleoside analogues. J Virol 2001; 75: 3105-10.
27. Gaudreau A, Hill E, Balfour HH, Erice A, Boivin G. Phenotypic and genotypic characterization of acyclovir-resistant herpes simplex virus from immunocompromised patients. J Infect Dis 1998; 178: 297-303.
28. Andrei G, Snoeck R, DeClercq E, Esnouf R, Fiten P, Opdenakker G. Resistance of herpes simplex virus type I against different phosphonylmethoxyalkyl derivatives of purines and pyrimidines due to specific mutations in the viral DNA polymerase gene. J Gen Virol 2000; 81: 639-48.
29. Schmit I, Boivin G. Characterization of the DNA polymerase and thymidine kinase genes of herpes simplex virus isolates from AIDS patients in whom acyclovir and foscarnet therapy sequentially failed. J Infect Dis 1999; 180: 487-90.
30. Talarico CL, Phelps WC, Biron KK. Analysis of thymidine kinase genes from acyclovir-resistant mutants of varicella-zoster virus isolates from patients with AIDS. J Virol 1993; 67: 1024-33.
31. Visse B, Dumont B, Huraux JM, Fillet AM. Single amino acid change in DNA polymerase is associated with foscarnet resistance in a varicella-zoster strain recovered from a patient with AIDS. J Infect Dis 1998; 178: S55-7.
32. Visse B, Huraux JM, Fillet AM. Point mutations in the varicella-zoster virus DNA polymerase gene confers resistance to foscarnet and slow growth phenotype. J Med Virol 1999; 59: 84-90.
33. Kamiyama T, Kurokawa M, Shiraki K. Characterization of the DNA polymerase gene of varicella-zoster viruses resistant to acyclovir. J Gen Virol 2001; 82: 2761-5.
34. Fletcher CV, Englund JA, Bean B, Chinnock B, Brundage DM, Balfour HHJr. Continuous infusion of high-dose acyclovir for serious herpesvirus infections. Antimicrob Agents Chemother 1989; 33: 1375-8.
35. Balfour HH Jr, Benson C, Braun J, et al. Management of acyclovir-resistant herpes simplex and varicella-zoster virus infections. J Acquir Immune Defic Syndr 1994; 7: 254-60.
36. Engel JP, Englund JA, Fletcher CV, Hill EL. Treatment of resistant herpes simplex virus with continuous-infusion acyclovir. JAMA 1990; 263: 1662-4.
37. Collins P, Oliver MM. Sensitivity monitoring of herpes simplex virus isolates from patients receiving acyclovir. J Antimicrobial Chem 1986; 18 (Suppl. B): 103-12.
38. Reusser P, Cordonnier C, Einsele H, et al. European survey of herpesvirus resistance to antiviral drugs in bone marrow transplant recipients. Bone Marrow Transplant 1996; 17: 813-7.
39. Snoeck R, Andrei G, Gerard M, et al. Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscanet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl) cytosine (HPMPC). Clin Infect Dis 1994; 18: 570-8.
40. LoPresti AE, Levine JF, Munk GB, Tai CY, Mendel DB. Successful treatment of an acyclovir- and foscarnet-resistant herpes simplex virus type 1 lesion with intravenous cidofovir. Clin Infect Dis 1998; 26: 512-3.
41. Blot N, Schneider P, Young P, et al. Treatment of an acyclovir and foscarnet-resistant herpes simplex virus infection with cidofovir in a child after an unrelated bone marrow transplant. Bone Marrow Transplant 2000; 26: 903-5.
42. Crute JJ, Grygon CA, Hargrave KD, et al. Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease. Nat Med 2002; 8: 386-91.
43. Kleymann G, Fisher R, Betz UA, et al. New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease. Nat Med 2002; 8: 392-8.
44. Dutia BM, Frame MC, Subak-Sharpe JH, Clark WN, Marsden HS. Specific inhibition of herpesvirus ribonucleotide reductase by synthetic peptides. Nature 2002; 321: 439-41.
45. Waxman L, Darke PL. The herpesvirus proteases as targets for antiviral chemotherapy. Antivir Chem Chemother 2000; 11: 1-22.